| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1004912037 |
| P356 | DOI | 10.1186/1756-0500-7-802 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1186/1756-0500-7-802 |
| P932 | PMC publication ID | 4247209 |
| P698 | PubMed publication ID | 25399834 |
| P5875 | ResearchGate publication ID | 268449512 |
| P2093 | author name string | Rahul Banerjee | |
| Ambarnil Ghosh | |||
| Nanda Ghoshal | |||
| Dhananjay Bhattacharyya | |||
| Barnali Waugh | |||
| P2860 | cites work | Leishmaniasis worldwide and global estimates of its incidence | Q21134611 |
| Proteomic analysis of the secretome of Leishmania donovani | Q21184106 | ||
| BLAST+: architecture and applications | Q21284368 | ||
| Comparative genomic analysis of three Leishmania species that cause diverse human disease | Q21972828 | ||
| The Genome of the African Trypanosome Trypanosoma brucei | Q22065798 | ||
| The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease | Q22065799 | ||
| Expansion of the BioCyc collection of pathway/genome databases to 160 genomes | Q24535096 | ||
| GeneDB--an annotation database for pathogens | Q24622411 | ||
| Genomic-scale prioritization of drug targets: the TDR Targets database | Q24635333 | ||
| Nucleoside hydrolase from Leishmania major. Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-å crystal structure | Q27619060 | ||
| Reversible ligand-induced dissociation of a tryptophan-shift mutant of phosphofructokinase from Bacillus stearothermophilus | Q27639863 | ||
| The crystal structure of Trypanosoma cruzi dUTPase reveals a novel dUTP/dUDP binding fold | Q27642947 | ||
| The Crystal Structure of the Leishmania major Deoxyuridine Triphosphate Nucleotidohydrolase in Complex with Nucleotide Analogues, dUMP, and Deoxyuridine | Q27667393 | ||
| The Leishmania donovani UMP Synthase Is Essential for Promastigote Viability and Has an Unusual Tetrameric Structure That Exhibits Substrate-controlled Oligomerization | Q27667488 | ||
| Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography | Q27671819 | ||
| OrthoMCL: Identification of Ortholog Groups for Eukaryotic Genomes | Q27860860 | ||
| Leishmania donovani phosphofructokinase. Gene characterization, biochemical properties and structure-modeling studies | Q44103737 | ||
| Scaffold hopping in drug discovery using inductive logic programming. | Q45915393 | ||
| Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design. | Q46627562 | ||
| Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed. | Q53130066 | ||
| Gene synteny and evolution of genome architecture in trypanosomatids | Q56877837 | ||
| Resistance to antimony and treatment failure in human Leishmania (Viannia) infection | Q83163388 | ||
| Scaffold hopping | Q88189333 | ||
| Dali server: conservation mapping in 3D | Q27860994 | ||
| Essential gene identification and drug target prioritization in Aspergillus fumigatus | Q28469156 | ||
| The druggable genome | Q29547361 | ||
| The MetaCyc Database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases | Q29615370 | ||
| Comparative genomics of trypanosomatid parasitic protozoa | Q29617953 | ||
| Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database | Q30494222 | ||
| Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness. | Q33256908 | ||
| Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis | Q33326935 | ||
| Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing | Q33400511 | ||
| EasyModeller: A graphical interface to MODELLER | Q33659530 | ||
| The Parasite-Specific Trypanothione Metabolism of Trypanosoma and Leishmania | Q33966094 | ||
| Deletion of UDP-glucose pyrophosphorylase reveals a UDP-glucose independent UDP-galactose salvage pathway in Leishmania major | Q33979086 | ||
| Topical paromomycin with or without gentamicin for cutaneous leishmaniasis | Q34326574 | ||
| Glycolysis as a target for the design of new anti-trypanosome drugs. | Q34341037 | ||
| Endosymbiosis in trypanosomatids: the genomic cooperation between bacterium and host in the synthesis of essential amino acids is heavily influenced by multiple horizontal gene transfers. | Q34369611 | ||
| Specificity of the trypanothione-dependent Leishmania major glyoxalase I: structure and biochemical comparison with the human enzyme | Q34487152 | ||
| Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda | Q34768663 | ||
| Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs | Q35569073 | ||
| Antimony resistance in leishmania, focusing on experimental research | Q35607561 | ||
| On a Cercopithifilaria sp. transmitted by Rhipicephalus sanguineus: a neglected, but widespread filarioid of dogs | Q35674822 | ||
| Adenine aminohydrolase from Leishmania donovani: unique enzyme in parasite purine metabolism | Q35802063 | ||
| Leishmaniasis: drugs in the clinic, resistance and new developments. | Q35943371 | ||
| Metabolic functions of glycosomes in trypanosomatids | Q36615403 | ||
| Molecular mechanisms of antimony resistance in Leishmania | Q36716130 | ||
| Adenylosuccinate synthetase and adenylosuccinate lyase deficiencies trigger growth and infectivity deficits in Leishmania donovani | Q36724945 | ||
| Insights into the redox biology of Trypanosoma cruzi: Trypanothione metabolism and oxidant detoxification | Q37202974 | ||
| Targeting Trypanothione Metabolism in Trypanosomatid Human Parasites | Q37782110 | ||
| The life-cycle of Leishmania in the sandfly with special reference to the form infective to the vertebrate host | Q38014538 | ||
| Proteinases as virulence factors in Leishmania spp. infection in mammals. | Q38032623 | ||
| Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods | Q38554461 | ||
| Novel biochemical pathways in parasitic protozoa | Q38715992 | ||
| Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists | Q40598596 | ||
| Biosynthesis of galactofuranose in kinetoplastids: novel therapeutic targets for treating leishmaniasis and chagas' disease | Q42752718 | ||
| The crystal structure of trypanothione reductase from the human pathogen Trypanosoma cruzi at 2.3 A resolution. | Q42844963 | ||
| Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE. | Q43610057 | ||
| Docking and molecular dynamics studies at trypanothione reductase and glutathione reductase active sites | Q44059307 | ||
| P921 | main subject | in silico | Q192572 |
| P304 | page(s) | 802 | |
| P577 | publication date | 2014-11-17 | |
| P1433 | published in | BMC Research Notes | Q15762797 |
| P1476 | title | In silico work flow for scaffold hopping in Leishmania | |
| P478 | volume | 7 |
| Q55240622 | In vitro screening of known drugs identified by scaffold hopping techniques shows promising leishmanicidal activity for suramin and netilmicin. | cites work | P2860 |
Search more.